Shares are up 44% on 2.4 million in volume on more than 15,900 trades as of this post. The stock is $2.48 a share. [mstock id="73007" asset="cyad"] https://www.businesswire.com/news/home/20220731005044/en/Celyad-Oncology-Announces-FDA-Lifts-Clinical-Hold-of-CYAD-101-002-Phase-1b-Trial